Cargando…

A Novel Dual PI3K/mTOR Inhibitor, XIN-10, for the Treatment of Cancer

An imbalance in PI3K/AKT/mTOR pathway signaling in humans often leads to cancer. Therefore, the investigation of anti-cancer medications that inhibit PI3K and mTOR has emerged as a significant area of research. The aim of this study was to explore the effect of XIN-10, a dual PI3K/mTOR inhibitor, on...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luo, Leixuan, Sun, Xin, Yang, Yang, Xia, Lulu, Wang, Shiyu, Fu, Yuxing, Zhu, Yuxuan, Xu, Shan, Zhu, Wufu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10573424/ https://www.ncbi.nlm.nih.gov/pubmed/37834269 http://dx.doi.org/10.3390/ijms241914821

Ejemplares similares

Design, Synthesis and Biological Evaluation of Novel Phenylsulfonylurea Derivatives as PI3K/mTOR Dual Inhibitors
por: Zhao, Bingbing, et al.
Publicado: (2018)

Recent Advances in Dual PI3K/mTOR Inhibitors for Tumour Treatment
por: Wu, Xianbo, et al.
Publicado: (2022)

Effect of WenXin KeLi on Improvement of Arrhythmia after Myocardial Infarction by Intervening PI3K-AKT-mTOR Autophagy Pathway
por: Lv, Meng, et al.
Publicado: (2022)

Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?
por: Tarantelli, Chiara, et al.
Publicado: (2020)

Efficacy of dual PI-3K and mTOR inhibitors in vitro and in vivo in acute lymphoblastic leukemia
por: Wong, Jacky, et al.
Publicado: (2014)

Structural insights of a PI3K/mTOR dual inhibitor with the morpholino-triazine scaffold
por: Takeda, Takako, et al.
Publicado: (2016)

Genotype-Dependent Efficacy of a Dual PI3K/mTOR Inhibitor, NVP-BEZ235, and an mTOR Inhibitor, RAD001, in Endometrial Carcinomas
por: Shoji, Keiko, et al.
Publicado: (2012)

Evaluation of a Dual PI3K/mTOR Inhibitor PF-04691502 against Bladder Cancer Cells
por: Shang, Xiaosong, et al.
Publicado: (2022)

Dual mTOR/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease
por: Liu, Yang, et al.
Publicado: (2018)

Dual PI3K/mTOR inhibitor NVP-BEZ235 decreases the proliferation of doxorubicin-resistant K562 cells
por: Li, Jie, et al.
Publicado: (2021)

BRD4 inhibition sensitizes renal cell carcinoma cells to the PI3K/mTOR dual inhibitor VS-5584
por: Xu, Ming, et al.
Publicado: (2020)

PI3K/Akt/mTOR inhibitors in breast cancer
por: Lee, Joycelyn JX, et al.
Publicado: (2015)

Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma
por: Chen, Ming-Huang, et al.
Publicado: (2014)

Inhibition of DNA methyltransferase as a novel therapeutic strategy to overcome acquired resistance to dual PI3K/mTOR inhibitors
por: Qian, Xiao-jun, et al.
Publicado: (2015)

Inhibition of autophagy sensitizes malignant pleural mesothelioma cells to dual PI3K/mTOR inhibitors
por: Echeverry, N, et al.
Publicado: (2015)

Developing a novel dual PI3K–mTOR inhibitor from the prodrug of a metabolite
por: Zhou, Yan, et al.
Publicado: (2017)

The dual PI3K/mTOR inhibitor dactolisib elicits anti-tumor activity in vitro and in vivo
por: Shi, Fei, et al.
Publicado: (2017)

The dual PI3K/mTOR inhibitor NVP-BEZ235 inhibits proliferation and induces apoptosis of burkitt lymphoma cells
por: Li, Chuntuan, et al.
Publicado: (2015)

Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway
por: Chen, Dongshao, et al.
Publicado: (2018)

Enhanced efficacy of histone deacetylase inhibitor panobinostat combined with dual PI3K/mTOR inhibitor BEZ235 against glioblastoma
por: Meng, Wei, et al.
Publicado: (2019)

The anti-tumor effects of dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A on inducing autophagy in esophageal squamous cell carcinoma
por: Wu, Ning, et al.
Publicado: (2018)

Correction: The dual PI3K/mTOR inhibitor dactolisib elicits anti-tumor activity in vitro and in vivo
por: Shi, Fei, et al.
Publicado: (2018)

SPR965, a Dual PI3K/mTOR Inhibitor, as a Targeted Therapy in Ovarian Cancer
por: Tran, Arthur-Quan, et al.
Publicado: (2021)

Design, Synthesis, and Biological Evaluation of Sulfonamide Methoxypyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors
por: Gao, Haotian, et al.
Publicado: (2023)

Identification of phytochemical as a dual inhibitor of PI3K and mTOR: a structure-based computational approach
por: Kumar, B. Harish, et al.
Publicado: (2022)

Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma
por: Erlich, R B, et al.
Publicado: (2012)

Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer
por: Zhu, Yan, et al.
Publicado: (2015)

Dual inhibitor of PI3K and mTOR (NVP-BEZ235) augments the efficacy of fluorouracil on gastric cancer chemotherapy
por: Li, Liangqing, et al.
Publicado: (2018)

PI3K/mTOR Dual Inhibitor PF-04691502 Is a Schedule-Dependent Radiosensitizer for Gastroenteropancreatic Neuroendocrine Tumors
por: Chow, Zeta, et al.
Publicado: (2021)

The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition
por: Haagensen, E J, et al.
Publicado: (2012)

PI3K/mTOR dual inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A synergistically exert anti-tumor activity in breast cancer
por: Chen, Liyan, et al.
Publicado: (2017)

Synthesis and bioevaluation of thienopyrimidines bearing a pyrazoline unit as selective PI3Kα inhibitors
por: Lai, Luogen, et al.
Publicado: (2019)

BET protein inhibition evidently enhances sensitivity to PI3K/mTOR dual inhibition in intrahepatic cholangiocarcinoma
por: Miao, Xiaolong, et al.
Publicado: (2021)

PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer
por: Zhu, Kunrui, et al.
Publicado: (2022)

PI3K/AKT/mTOR Pathway in Angiogenesis
por: Karar, Jayashree, et al.
Publicado: (2011)

Targeting PI3K/mTOR Signaling in Cancer
por: Arcaro, Alexandre
Publicado: (2014)

Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines
por: Xin, Pengliang, et al.
Publicado: (2017)

Suppression of PI3K/Akt/mTOR/c-Myc/mtp53 Positive Feedback Loop Induces Cell Cycle Arrest by Dual PI3K/mTOR Inhibitor PQR309 in Endometrial Cancer Cell Lines
por: Hsin, I-Lun, et al.
Publicado: (2021)

Synergistic antitumor effect of dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with cisplatin on drug-resistant non-small cell lung cancer cell
por: Zhu, Hao, et al.
Publicado: (2020)

Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib
por: Roulin, Didier, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_vh6supqiht8134lcv37gpbboie